Genomed SA
WSE:GEN

Watchlist Manager

Genomed SA

WSE:GEN

Watchlist

Dividends

Discount Rate

Price: 27.2 PLN 3.82%

Market Cap: 35.9m PLN

Have any thoughts about
Genomed SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 27.2 PLN

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

GEN Alert

Genomed SA

27.2

+1.0 (+3.82%)

52 Week Range	26.2 33.4
Price Target

We'll email you a reminder when the closing price reaches PLN.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Genomed SA

What unique competitive advantages
does Genomed SA hold over its rivals?

What risks and challenges
does Genomed SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Genomed SA.

What unique competitive advantages
does Genomed SA hold over its rivals?

What risks and challenges
does Genomed SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Genomed SA.

Provide P/S
for Genomed SA.

Provide P/E
for Genomed SA.

Provide P/OCF
for Genomed SA.

Provide P/FCFE
for Genomed SA.

Provide P/B
for Genomed SA.

Provide EV/S
for Genomed SA.

Provide EV/GP
for Genomed SA.

Provide EV/EBITDA
for Genomed SA.

Provide EV/EBIT
for Genomed SA.

Provide EV/OCF
for Genomed SA.

Provide EV/FCFF
for Genomed SA.

Provide EV/IC
for Genomed SA.

Compare the intrinsic valuations
of Genomed SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Genomed SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Genomed SA compared to its peers.

Compare the P/E ratios
of Genomed SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Genomed SA with its peers.

Analyze the financial leverage
of Genomed SA compared to its main competitors.

Show all profitability ratios
for Genomed SA.

Provide ROE
for Genomed SA.

Provide ROA
for Genomed SA.

Provide ROIC
for Genomed SA.

Provide ROCE
for Genomed SA.

Provide Gross Margin
for Genomed SA.

Provide Operating Margin
for Genomed SA.

Provide Net Margin
for Genomed SA.

Provide FCF Margin
for Genomed SA.

Show all solvency ratios
for Genomed SA.

Provide D/E Ratio
for Genomed SA.

Provide D/A Ratio
for Genomed SA.

Provide Interest Coverage Ratio
for Genomed SA.

Provide Altman Z-Score Ratio
for Genomed SA.

Provide Quick Ratio
for Genomed SA.

Provide Current Ratio
for Genomed SA.

Provide Cash Ratio
for Genomed SA.

What is the historical Revenue growth
over the last 5 years for Genomed SA?

What is the historical Net Income growth
over the last 5 years for Genomed SA?

What is the current Free Cash Flow
of Genomed SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Genomed SA.

GEN

Balance Sheet

Cash & Cash Equivalents

Genomed SA
Cash & Cash Equivalents

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Genomed SA
Cash & Cash Equivalents Peer Comparison

Comparables:

MAB

RDG

BIO

URT

SVE

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company		Cash & Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
G	Genomed SA WSE:GEN	Cash & Cash Equivalents zł5.3m	CAGR 3-Years 5%	CAGR 5-Years 8%	CAGR 10-Years N/A
M	Mabion SA WSE:MAB	Cash & Cash Equivalents zł50.2m	CAGR 3-Years -13%	CAGR 5-Years 10%	CAGR 10-Years 11%
R	Read Gene SA WSE:RDG	Cash & Cash Equivalents N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
B	Bioton SA WSE:BIO	Cash & Cash Equivalents zł3.9m	CAGR 3-Years -6%	CAGR 5-Years -11%	CAGR 10-Years -21%
U	Urteste SA WSE:URT	Cash & Cash Equivalents zł1.1m	CAGR 3-Years 39%	CAGR 5-Years N/A	CAGR 10-Years N/A
S	Synthaverse SA WSE:SVE	Cash & Cash Equivalents zł11.2m	CAGR 3-Years 124%	CAGR 5-Years 43%	CAGR 10-Years 23%

What is Genomed SA's Cash & Cash Equivalents?

Cash & Cash Equivalents
5.3m PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Cash & Cash Equivalents amounts to 5.3m PLN.

What is Genomed SA's Cash & Cash Equivalents growth rate?

Cash & Cash Equivalents CAGR 5Y
8%

Over the last year, the Cash & Cash Equivalents growth was 51%. The average annual Cash & Cash Equivalents growth rates for Genomed SA have been 5% over the past three years , 8% over the past five years .

Genomed SA
WSE:GEN

Genomed SA
Cash & Cash Equivalents

Genomed SA
Cash & Cash Equivalents Peer Comparison

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

See Also

What is Genomed SA's Cash & Cash Equivalents?

Cash & Cash Equivalents
5.3m PLN

What is Genomed SA's Cash & Cash Equivalents growth rate?

Cash & Cash Equivalents CAGR 5Y
8%

Company

Help

Tools

Stocks

Genomed SA WSE:GEN

Genomed SA Cash & Cash Equivalents

Genomed SA Cash & Cash Equivalents Peer Comparison

Competitive Cash & Cash Equivalents Analysis Latest Figures & CAGR of Competitors

See Also

What is Genomed SA's Cash & Cash Equivalents? Cash & Cash Equivalents 5.3m PLN

What is Genomed SA's Cash & Cash Equivalents growth rate? Cash & Cash Equivalents CAGR 5Y 8%

Company

Help

Tools

Stocks

Genomed SA
WSE:GEN

Genomed SA
Cash & Cash Equivalents

Genomed SA
Cash & Cash Equivalents Peer Comparison

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

What is Genomed SA's Cash & Cash Equivalents?

Cash & Cash Equivalents
5.3m PLN

What is Genomed SA's Cash & Cash Equivalents growth rate?

Cash & Cash Equivalents CAGR 5Y
8%